Wird geladen...
Certolizumab pegol: a new biologic targeting rheumatoid arthritis
The past decade has been an exciting period for clinical research and patient care in rheumatoid arthritis. This is mostly due to targeted biologic agents that have changed the outcome of this disease. Certolizumab pegol (Cimzia®, UCB Inc., GA, USA), which targets TNF-α with a different mechanism of...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2010
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3971417/ https://ncbi.nlm.nih.gov/pubmed/20979550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/eci.10.69 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|